Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
15173 | 727 | 36.2 | 68% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
307 | 3 | INTEGRIN//ALPORT SYNDROME//LAMININ | 40384 |
2579 | 2 | HUMANIZED MICE//ORTHOTOPIC IMPLANTATION//SCID MICE | 3666 |
15173 | 1 | PATIENT DERIVED XENOGRAFT//FP3//PDX | 727 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | PATIENT DERIVED XENOGRAFT | authKW | 373683 | 4% | 29% | 31 |
2 | FP3 | authKW | 216001 | 1% | 86% | 6 |
3 | PDX | authKW | 137439 | 2% | 27% | 12 |
4 | PATIENT DERIVED TUMOR XENOGRAFT | authKW | 95450 | 1% | 45% | 5 |
5 | TUMORGRAFTS | authKW | 95450 | 1% | 45% | 5 |
6 | PATIENT DERIVED CELL | authKW | 84001 | 0% | 100% | 2 |
7 | XENOGRAFT | authKW | 79750 | 8% | 3% | 55 |
8 | AFFILIATED ZHUJI HOSP | address | 74994 | 1% | 36% | 5 |
9 | TUMOR XENOGRAFT MODELS | authKW | 74663 | 1% | 44% | 4 |
10 | ANTIANGIOGENIC EFFECT | authKW | 69994 | 1% | 33% | 5 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 11141 | 63% | 0% | 460 |
2 | Pathology | 340 | 7% | 0% | 49 |
3 | Medicine, Research & Experimental | 165 | 7% | 0% | 49 |
4 | Cell Biology | 158 | 9% | 0% | 69 |
5 | CYTOLOGY & HISTOLOGY | 130 | 1% | 0% | 5 |
6 | Otorhinolaryngology | 52 | 2% | 0% | 16 |
7 | Urology & Nephrology | 33 | 3% | 0% | 20 |
8 | Mathematical & Computational Biology | 18 | 1% | 0% | 9 |
9 | Pharmacology & Pharmacy | 17 | 6% | 0% | 41 |
10 | Statistics & Probability | 11 | 2% | 0% | 11 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | AFFILIATED ZHUJI HOSP | 74994 | 1% | 36% | 5 |
2 | UNITE RECH TRANSLAT | 55999 | 0% | 67% | 2 |
3 | ZHEJIANG CANC HOSP | 51687 | 1% | 31% | 4 |
4 | ADV CANC THER EUT | 42001 | 0% | 100% | 1 |
5 | ADV TECHNOL PARTNERSHIP INITIAT | 42001 | 0% | 100% | 1 |
6 | BEIJING CANC HOSP THORAC MED ONCOL | 42001 | 0% | 100% | 1 |
7 | BELFER PL CANC SCI DERMATOL | 42001 | 0% | 100% | 1 |
8 | BREAST BIOL GRPMANCHESTER CANC | 42001 | 0% | 100% | 1 |
9 | CANC CLIN TRIALS CANADA CLIN TRIALS GRP | 42001 | 0% | 100% | 1 |
10 | CANC SURG METAB GRP | 42001 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | EXPERIMENTAL CELL BIOLOGY | 12589 | 2% | 3% | 11 |
2 | CLINICAL CANCER RESEARCH | 2860 | 4% | 0% | 32 |
3 | EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 2681 | 2% | 1% | 11 |
4 | ADVANCES IN PHARMACOLOGY AND CHEMOTHERAPY | 2331 | 0% | 6% | 1 |
5 | ANTICANCER RESEARCH | 1811 | 4% | 0% | 29 |
6 | CANCER RESEARCH | 1673 | 6% | 0% | 40 |
7 | ONCOTARGET | 1626 | 3% | 0% | 22 |
8 | CANCER CLINICAL TRIALS | 1309 | 0% | 2% | 2 |
9 | BRITISH JOURNAL OF CANCER | 1103 | 3% | 0% | 22 |
10 | ZEITSCHRIFT FUR VERSUCHSTIERKUNDE | 978 | 0% | 1% | 3 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | PATIENT DERIVED XENOGRAFT | 373683 | 4% | 29% | 31 | Search PATIENT+DERIVED+XENOGRAFT | Search PATIENT+DERIVED+XENOGRAFT |
2 | FP3 | 216001 | 1% | 86% | 6 | Search FP3 | Search FP3 |
3 | PDX | 137439 | 2% | 27% | 12 | Search PDX | Search PDX |
4 | PATIENT DERIVED TUMOR XENOGRAFT | 95450 | 1% | 45% | 5 | Search PATIENT+DERIVED+TUMOR+XENOGRAFT | Search PATIENT+DERIVED+TUMOR+XENOGRAFT |
5 | TUMORGRAFTS | 95450 | 1% | 45% | 5 | Search TUMORGRAFTS | Search TUMORGRAFTS |
6 | PATIENT DERIVED CELL | 84001 | 0% | 100% | 2 | Search PATIENT+DERIVED+CELL | Search PATIENT+DERIVED+CELL |
7 | XENOGRAFT | 79750 | 8% | 3% | 55 | Search XENOGRAFT | Search XENOGRAFT |
8 | TUMOR XENOGRAFT MODELS | 74663 | 1% | 44% | 4 | Search TUMOR+XENOGRAFT+MODELS | Search TUMOR+XENOGRAFT+MODELS |
9 | ANTIANGIOGENIC EFFECT | 69994 | 1% | 33% | 5 | Search ANTIANGIOGENIC+EFFECT | Search ANTIANGIOGENIC+EFFECT |
10 | LOG10 CELL KILL | 55999 | 0% | 67% | 2 | Search LOG10+CELL+KILL | Search LOG10+CELL+KILL |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | SIOLAS, D , HANNON, GJ , (2013) PATIENT-DERIVED TUMOR XENOGRAFTS: TRANSFORMING CLINICAL SAMPLES INTO MOUSE MODELS.CANCER RESEARCH. VOL. 73. ISSUE 17. P. 5315-5319 | 24 | 65% | 156 |
2 | TENTLER, JJ , TAN, AC , WEEKES, CD , JIMENO, A , LEONG, S , PITTS, TM , ARCAROLI, JJ , MESSERSMITH, WA , ECKHARDT, SG , (2012) PATIENT-DERIVED TUMOUR XENOGRAFTS AS MODELS FOR ONCOLOGY DRUG DEVELOPMENT.NATURE REVIEWS CLINICAL ONCOLOGY. VOL. 9. ISSUE 6. P. 338 -350 | 37 | 35% | 252 |
3 | IZUMCHENKO, E , MEIR, J , BEDI, A , WYSOCKI, PT , HOQUE, MO , SIDRANSKY, D , (2016) PATIENT-DERIVED XENOGRAFTS AS TOOLS IN PHARMACEUTICAL DEVELOPMENT.CLINICAL PHARMACOLOGY & THERAPEUTICS. VOL. 99. ISSUE 6. P. 612 -621 | 38 | 56% | 0 |
4 | CHO, SY , KANG, W , HAN, JY , MIN, S , KANG, J , LEE, A , KWON, JY , LEE, C , PARK, H , (2016) AN INTEGRATIVE APPROACH TO PRECISION CANCER MEDICINE USING PATIENT-DERIVED XENOGRAFTS.MOLECULES AND CELLS. VOL. 39. ISSUE 2. P. 77 -86 | 32 | 48% | 3 |
5 | CHOI, YY , LEE, JE , KIM, H , SIM, MH , KIM, KK , LEE, G , KIM, HI , AN, JY , HYUNG, WJ , KIM, CB , ET AL (2016) ESTABLISHMENT AND CHARACTERISATION OF PATIENT-DERIVED XENOGRAFTS AS PARACLINICAL MODELS FOR GASTRIC CANCER.SCIENTIFIC REPORTS. VOL. 6. ISSUE . P. - | 31 | 56% | 1 |
6 | SIA, D , MOEINI, A , LABGAA, I , VILLANUEVA, A , (2015) THE FUTURE OF PATIENT-DERIVED TUMOR XENOGRAFTS IN CANCER TREATMENT.PHARMACOGENOMICS. VOL. 16. ISSUE 14. P. 1671 -1683 | 39 | 41% | 2 |
7 | BROWN, KM , XUE, AQ , MITTAL, A , SAMRA, JS , SMITH, R , HUGH, TJ , (2016) PATIENT-DERIVED XENOGRAFT MODELS OF COLORECTAL CANCER IN PRECLINICAL RESEARCH: A SYSTEMATIC REVIEW.ONCOTARGET. VOL. 7. ISSUE 40. P. 66212 -66225 | 33 | 47% | 0 |
8 | HIDALGO, M , AMANT, F , BIANKIN, AV , BUDINSKA, E , BYRNE, AT , CALDAS, C , CLARKE, RB , DE JONG, S , JONKERS, J , MAELANDSMO, GM , ET AL (2014) PATIENT-DERIVED XENOGRAFT MODELS: AN EMERGING PLATFORM FOR TRANSLATIONAL CANCER RESEARCH.CANCER DISCOVERY. VOL. 4. ISSUE 9. P. 998 -1013 | 25 | 36% | 115 |
9 | ALKEMA, NG , TOMAR, T , DUIKER, EW , MEERSMA, GJ , KLIP, H , VAN DER ZEE, AGJ , WISMAN, GBA , DE JONG, S , (2015) BIOBANKING OF PATIENT AND PATIENT-DERIVED XENOGRAFT OVARIAN TUMOUR TISSUE: EFFICIENT PRESERVATION WITH LOW AND HIGH FETAL CALF SERUM BASED METHODS.SCIENTIFIC REPORTS. VOL. 5. ISSUE . P. - | 26 | 60% | 0 |
10 | JIN, KT , TENG, LS , SHEN, YP , HE, KF , XU, ZZ , LI, GL , (2010) PATIENT-DERIVED HUMAN TUMOUR TISSUE XENOGRAFTS IN IMMUNODEFICIENT MICE: A SYSTEMATIC REVIEW.CLINICAL & TRANSLATIONAL ONCOLOGY. VOL. 12. ISSUE 7. P. 473-480 | 25 | 54% | 63 |
Classes with closest relation at Level 1 |